ImrecoxibAlternative Names: BAP 909
Latest Information Update: 22 Apr 2016
At a glance
- Originator Institute of Materia Medica
- Developer Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Pyrroles; Small molecules; Sulfides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoarthritis
- Clinical Phase Unknown Inflammation
Most Recent Events
- 22 Dec 2015 Jiangsu HengRui Medicine Co. initiates a phase I drug-drug interaction trial in Healthy volunteers in China (PO) (ChiCTR-OIB-15007606)
- 01 Jan 2015 Phase-I clinical trials in Osteoarthritis (In volunteers) in China (unspecified route) (NCT02426060)
- 01 Jan 2015 Jiangsu HengRui Medicine Co. initiates enrolment in a phase I trial for Osteoarthritis in China (NCT02456688)